Skip Navigation
Skip to contents

대한신장학회


간행물 검색

현재 페이지 경로
  • HOME
  • 간행물
  • 간행물 검색
논문분류 춘계학술대회 초록집
제목 Largest cohort study of Post-COVID-19 mucormycosis: A concerning report from India
저자 Hari Meshram, Vivek Kute, Himanshu Patel, Sanshriti Chauhan, Subho Banerjee, Ruchir Dave, Sudeep Desai
출판정보 2021; 2021(1):
키워드
초록 Objective: We did a comprehensive analysis of 11 mucormycosis cases in kidney transplant recipients (KTR) who recovered from SARS-CoV2 (n = 335) in IKDRC, Ahmedabad, Gujarat, India during the study period from May 2020 to April 2021. Methods: The incidence of post-COVID-19 mucormycosis increased exponentially from 0.8% (2 of 225) in the first wave to 9% (10 of 110) in the second. The median age (interquartile range, range) of the cohort was 42(33.5-50, 26-60) years with 54.5% diabetes. COVID-19 severity ranged from mild (n=10) to severe cases (n=1). The duration from COVID-19 discharge to readmission was 7(7-7, 4-14) days. Ten cases were Rhino-orbital-cerebral-mucormycosis (ROCM) and one had pulmonary mucormycosis. Functional endoscopic sinus surgery (FESS) was performed in all cases of ROCM. The duration of antifungal therapy was 24(21-28.5, 17-40) days. The mortality rate reported was 27%. Results:  To date, this represents the largest cohort of post-COVID-19 mucormycosis in transplantation. The morbidity and mortality with post-COVID-19 mucormycosis are high. Judicious use of steroids should be done along with strict control of blood sugars. Preparedness and early identification is the key to improve the outcomes. Conclusions: Objective: Severe acute respiratory syndrome coronavirus (SARS-CoV2) sequelae in the transplant population are scarcely reported. Mucormycosis is one of such sequelae, which was a rare entity before the pandemic.   Methods: We did a comprehensive analysis of 11 mucormycosis cases in kidney transplant recipients (KTR) who recovered from SARS-CoV2 (n = 335) in IKDRC, Ahmedabad, Gujarat, India during the study period from May 2020 to April 2021. Results: The incidence of post-COVID-19 mucormycosis increased exponentially from 0.8% (2 of 225) in the first wave to 9% (10 of 110) in the second. The median age (interquartile range, range) of the cohort was 42(33.5-50, 26-60) years with 54.5% diabetes. COVID-19 severity ranged from mild (n=10) to severe cases (n=1). The duration from COVID-19 discharge to readmission was 7(7-7, 4-14) days. Ten cases were Rhino-orbital-cerebral-mucormycosis (ROCM) and one had pulmonary mucormycosis. Functional endoscopic sinus surgery (FESS) was performed in all cases of ROCM. The duration of antifungal therapy was 24(21-28.5, 17-40) days. The mortality rate reported was 27%. Conclusions:  To date, this represents the largest cohort of post-COVID-19 mucormycosis in transplantation. The morbidity and mortality with post-COVID-19 mucormycosis are high. Judicious use of steroids should be done along with strict control of blood sugars. Preparedness and early identification is the key to improve the outcomes.
원문(PDF) PDF 원문보기
위로가기